Comparison of intestinal metabolism for CYP3A substrates between rats and humans

被引：0
|
作者：
Kadono, Keitaro [1 ]
Naritomi, Yoichi [1 ]
Tabata, Kenji [1 ]
机构：
[1] Astellas Pharma Inc, Ibaraki, Japan
来源：
DRUG METABOLISM REVIEWS | 2015年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P208
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [31] Evaluation of drug interaction potential of CYP3A substrates - a tailored approach based on FM,CYP3A
    Sato, Masanobu
    Liu, Qi
    Yoshida, Kenta
    Li, Li
    Rekic, Dinko
    Reynolds, Kellie
    Zhang, Lei
    Huang, Shiew Mei
    Sinha, Vikram
    Zhao, Ping
    DRUG METABOLISM REVIEWS, 2016, 48 : 70 - 71
  • [32] Ambient tonicity and intestinal cytochrome CYP3A
    Chuang, Andrew I.
    Ito, Shinya
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (08) : 883 - 893
  • [33] Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans
    Hohmann, Nicolas
    Reinhard, Raphael
    Schnaidt, Sven
    Witt, Lukas
    Carls, Alexandra
    Burhenne, Jurgen
    Mikus, Gerd
    Haefeli, Walter E.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (08) : 2241 - 2247
  • [34] CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition
    Kharasch, ED
    Thummel, KE
    Watkins, PB
    MOLECULAR INTERVENTIONS, 2005, 5 (03) : 151 - +
  • [35] Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
    Richard B. Kirn
    Christoph Wandel
    Brenda Leake
    Mirjana Cvetkovic
    Martin F. Fromm
    Peter J. Dempsey
    Mark M. Roden
    Frank Belas
    Ajai K. Chaudhary
    Dan M. Roden
    Alastair J. J. Wood
    Grant R. Wilkinson
    Pharmaceutical Research, 1999, 16 (3) : 408 - 414
  • [36] Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
    Kim, RB
    Wandel, C
    Leake, B
    Cvetkovic, M
    Fromm, MF
    Dempsey, PJ
    Roden, MM
    Belas, F
    Chaudhary, AK
    Roden, DM
    Wood, AJJ
    Wilkinson, GR
    PHARMACEUTICAL RESEARCH, 1999, 16 (03) : 408 - 414
  • [37] Species Differences in Mechanism-Based Inactivation of CYP3A in Humans, Rats and Mice
    Aueviriyavit, Sasitorn
    Kobayashi, Kaoru
    Chiba, Kan
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (01) : 93 - 100
  • [38] METABOLIC SYNDROME REDUCES HEPATIC AND INTESTINAL CYP3A DRUG METABOLISM ACTIVITY.
    Gagnon, P.
    Levac, X.
    Kaddar, N.
    Ait-Zaid, K.
    Pilote, S.
    Patoine, D.
    Drolet, B.
    Simard, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S28 - S28
  • [39] Effects of CYP3A inhibition on the metabolism of cilostazol
    Suri, A
    Forbes, WP
    Bramer, SL
    CLINICAL PHARMACOKINETICS, 1999, 37 (Suppl 2) : 61 - 68
  • [40] Effects of CYP3A Inhibition on the Metabolism of Cilostazol
    Ajit Suri
    William P. Forbes
    Steven L. Bramer
    Clinical Pharmacokinetics, 1999, 37 : 61 - 68
12345